David Anderson, PhD
Chief Scientific Officer, Ivogen (Subsidiary of Nanova Biomaterials, Inc.)
David has deep expertise in target-based drug discovery and development and personalized molecular diagnostics in inflammation/immunology, oncology, microbiology, and bone biology. He is an accomplished leader in medical research and product development with experience as a research scientist, director of research, and executive leader in the pharmaceutical industry and biotechnology.
As an entrepreneur, he built and managed innovative drug discovery and development companies. He was a leader of teams responsible for the development of five approved drugs (Procrit®, Leustatin®, and Revlimid® for hematology/oncology indications and Zubrin® for veterinary arthritis use, and Surfaxin® for respiratory distress syndrome), nine INDs, and two Personalized Diagnostic products for rheumatoid arthritis (AVISE-PG® & AVISE-MCV®). David effectively managed human, technical, and financial resources, represented start-up companies to venture capital and banking firms to raise over $150M, partnered with world-class biopharmaceutical companies for $150M in milestone/equity payments, received over $4M in SBIR grants, and conducted research leading to the first $1B biotechnology product, Procrit® (Johnson & Johnson).
He has established translational research with world-class academic investigators to enhance and compliment expertise for successful research and product development. He has served as a consultant for numerous companies, VC and investment firms and as an SAB member.
David received a Ph.D. from The University of Missouri in medical microbiology and immunology and has held academic positions at the University of Colorado Health Sciences Center, The Scripps Research Institution and Graceland University. He has organized, chaired, and spoken at international conferences focused on discovery and development of novel anti-inflammatory/immunomodulatory and cancer drugs, and has refereed articles for peer-reviewed journals including Science, The Journal of Rheumatology, and Journal of Pharmacology and Experimental Therapeutics. David has an outstanding record of scientific publications and presentations with 32 peer-reviewed publications and more than 50 presentations/abstracts. Also, he has received a number of awards and five patents for his innovative research.